These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31990343)

  • 1. Pharmacokinetics of trimethoprim/sulfametrole in critically ill patients on continuous renal replacement therapy.
    Welte R; Beyer R; Hotter J; Broeker A; Wicha SG; Gasperetti T; Ranke P; Zaruba MM; Lorenz I; Eschertzhuber S; Ströhle M; Bellmann-Weiler R; Joannidis M; Bellmann R
    J Antimicrob Chemother; 2020 May; 75(5):1237-1241. PubMed ID: 31990343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.
    Pea F; Viale P; Pavan F; Furlanut M
    Clin Pharmacokinet; 2007; 46(12):997-1038. PubMed ID: 18027987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study.
    Hayakawa M; Ito Y; Fujita I; Iseki K; Gando S
    ASAIO J; 2006; 52(4):398-403. PubMed ID: 16883119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.
    Dubinsky S; Watt K; Saleeb S; Ahmed B; Carter C; Yeung CHT; Edginton A
    Clin Pharmacokinet; 2022 Feb; 61(2):189-229. PubMed ID: 34846703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
    Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
    J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
    Li S; Xie F
    Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
    Wang C; Chen J; Yang B; Li S; Zhang Y; Chen L; Wang T; Dong Y
    Pharmacotherapy; 2023 Mar; 43(3):180-188. PubMed ID: 36714991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy.
    Xie F; Li S; Cheng Z
    J Antimicrob Chemother; 2020 Jun; 75(6):1559-1566. PubMed ID: 32083673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.
    Petersson J; Giske CG; Eliasson E
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing.
    Muilwijk EW; de Lange DW; Schouten JA; Wasmann RE; Ter Heine R; Burger DM; Colbers A; Haas PJ; Verweij PE; Pickkers P; Brüggemann RJ
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32816723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy.
    Vaara S; Pettila V; Kaukonen KM
    Acta Anaesthesiol Scand; 2012 Feb; 56(2):147-57. PubMed ID: 22092254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.